In vitro activity of ceftazidime-avibactam against carbapenem-resistant and hypervirulent klebsiella pneumoniae isolates

Fangyou Yu, Jingnan Lv, Siqiang Niu, Hong Du, Yi Wei Tang, Robert A. Bonomo, Barry N. Kreiswirth, Liang Chen

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Carbapenem-resistant and hypervirulent Klebsiella pneumoniae (CR-hvKp) strains have emerged while antimicrobial treatment options remain limited. Herein, we tested the in vitro activity of ceftazidime-avibactam and other comparator antibiotics against 65 CR-hvKp isolates. Ceftazidime-avibactam, colistin, and tigecycline are highly active in vitro against CR-hvKp isolates (MIC90, 1 g/ml), including K. pneumoniae carbapenemase 2 (KPC-2)-producing ST11 CR-hvKp. On the basis of previous clinical experience and the in vitro data presented herein, we posit that ceftazidime-avibactam is a therapeutic option against CR-hvKp infections.

Original languageEnglish (US)
Article numbere01031-18
JournalAntimicrobial agents and chemotherapy
Volume62
Issue number8
DOIs
StatePublished - Aug 2018

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Keywords

  • Carbapenem resistance
  • Ceftazidime-avibactam
  • Hypervirulent Klebsiella pneumoniae
  • Susceptibility

Fingerprint

Dive into the research topics of 'In vitro activity of ceftazidime-avibactam against carbapenem-resistant and hypervirulent klebsiella pneumoniae isolates'. Together they form a unique fingerprint.

Cite this